PFx Biotech SRL
PFx Biotech reported total assets of 593,378 € at the end of the 2025 financial year (annual accounts filed with the NBB on 07 May 2026).
The score of PFx Biotech shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
PFx Biotech's annual accounts
| 2025 | |
|---|---|
| Net result | 2,547 € |
| Equity | 5,547 € |
| Cash | 432,157 € |
| EBITDA | 7,005 € |
| Total assets | 593,378 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 07 May 2026
PFx Biotech's financial analysis
- Solvency0.9%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of PFx Biotech
PFx Biotech's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1009.235.708
- VAT number
- BE1009235708
- Peppol
- Registered · 0208:1009235708 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 08 May 2024
- Registered office
- 9052 Ghent
- Latest accounts
- 2025 · filed on 07 May 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
PFx Biotech (SRL) has been based in Ghent since 2024, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 2,547 € and equity of 5,547 €; its revenue is not published. Its solvency stands at 0.9%, below the median of its sector (60.4%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to PFx Biotech
Companies in the same business, of comparable size and area, outside its group.
- TRACKS&Co Research and experimental development on natural sciences and engineering Jurbise · balance sheet 528,835 €
- CTTec Research and experimental development on natural sciences and engineering Menen · balance sheet 259,750 €
- Semaphar Research and experimental development on natural sciences and engineering Jodoigne · balance sheet 579,404 €
- MDTrials Research and experimental development on natural sciences and engineering Bruges · balance sheet 372,427 €
- Huisarts Nadine Costers Research and experimental development on natural sciences and engineering Knokke-Heist · balance sheet 502,719 €
- Dr.Awada Ahmad Hussein Research and experimental development on natural sciences and engineering Ternat · balance sheet 751,166 €
- Amador Bioscience Research and experimental development on natural sciences and engineering Hasselt · balance sheet €1.22m
- NorthboundBio Research and experimental development on natural sciences and engineering Leuven · balance sheet 286,592 €
Frequently asked questions about PFx Biotech
What is the revenue of PFx Biotech?
PFx Biotech files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of PFx Biotech?
In Belgium, the VAT number is the company number prefixed with BE: BE1009235708 for PFx Biotech, if the company is VAT-registered. Its company number (CBE) is 1009.235.708.
Where is the registered office of PFx Biotech?
According to the CBE register, the registered office of PFx Biotech is in 9052 Ghent.
What is the equity of PFx Biotech?
At the close of the 2025 financial year, the equity of PFx Biotech amounts to 5,547 €, a solvency of 0.9% of total assets.
Who manages PFx Biotech?
The register lists 1 active mandates at PFx Biotech. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of PFx Biotech
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →